Combination therapies in non-clear-cell renal cell carcinoma

Affiliations

¹ Department of Medical Oncology, Gazi University, Ankara 06000, Türkiye. Electronic address: dr.volcanaslan@gmail.com.
² Department of Medical Oncology, Gazi University, Ankara 06000, Türkiye.

Comment

Volkan Aslan et al. Lancet Oncol. 2023 Oct.

. 2023 Oct;24(10):e401.

doi: 10.1016/S1470-2045(23)00393-5.

¹ Department of Medical Oncology, Gazi University, Ankara 06000, Türkiye. Electronic address: dr.volcanaslan@gmail.com.
² Department of Medical Oncology, Gazi University, Ankara 06000, Türkiye.

No abstract available

Conflict of interest statement

We declare no competing interests.

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH. Albiges L, et al. Lancet Oncol. 2023 Aug;24(8):881-891. doi: 10.1016/S1470-2045(23)00276-0. Epub 2023 Jul 11. Lancet Oncol. 2023. PMID: 37451291 Clinical Trial.